checkAd

     189  0 Kommentare ProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing - Seite 3

    For ProQR Therapeutics N.V.

    Investor contact:
    Sarah Kiely
    ProQR Therapeutics N.V.
    T: +1 617 599 6228
    skiely@proqr.com
    or
    Peter Kelleher
    LifeSci Advisors
    T: +1 617 430 7579
    pkelleher@lifesciadvisors.com

    Lesen Sie auch

    Media contact:
    Robert Stanislaro
    FTI Consulting
    T: +1 212 850 5657
    robert.stanislaro@fticonsulting.com



    globenewswire
    0 Follower
    Autor folgen
    Seite 3 von 3

    Verfasst von globenewswire
    ProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing - Seite 3 LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) - ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended …